The US Court of Appeals for the Federal Circuit has upheld an earlier ruling that Indivior cannot stop two competitors from making a generic version of one of its drugs.
A German court has found that Sanofi’s high-cholesterol treatment, Praluent, infringes one of Amgen’s patents.
Reckitt Benckiser has agreed to pay a $1.4 billion fine to settle a US investigation into the sales and marketing of opioid addiction treatment Suboxone film by its former prescriptions business.
US-based biotechnology company Genentech, a subsidiary of Roche, has entered into a settlement agreement with Samsung Bioepis, ending all patent litigation between the two companies.
The UK Intellectual Property Office has today, July 5, opened a consultation into supplementary protection certificate law in the event of a ‘no deal’ Brexit.
The controversial supplementary protection certificate manufacturing waiver has come into force today, July 1.
A US court has issued an injunction barring the manufacture of generic versions of Swiss pharmaceutical company Novartis’ multiple sclerosis drug Gileyna.
The US Court of Appeals for the Federal Circuit yesterday, June 24, upheld a lower court’s finding that UCB’s patent is infringed by a planned generic version of Neupro, a patch to treat Parkinson’s disease.
A US court has upheld a decision that eight claims of one of Mayne Pharma’s patents are unpatentable for obviousness over prior art after a validity challenge was brought by a subsidiary of Merck & Co.
Generic medicines can cost up to 30 times more in poor countries, according to a new study.